Introduction of new vaccines into affluent countries has occurred at a breathtaking pace in recent years. By comparison, few new-generation vaccines have been introduced into public health programs for the poor in developing countries, and, for those that have, introduction has been painfully slow. Limited financial resources have retarded the introduction. However, the slow pace also stems from a dearth of evidence needed for rational policy decisions. Inadequate support to conduct phase 1 studies of vaccine candidates targeted against diseases of developing countries is a well-known obstacle. Additionally, other types of translational research are needed to generate the necessary evidence for policy. Many vaccines have been shown to perform less well in impoverished populations in the developing world than in persons residing in more affluent countries. Consequently, phase 2 and phase 3 trials are a second essential type of translational research needed for the introduction of vaccines in developing countries. Moreover, even for vaccines that achieve licensure via clinical trials in developing countries, doubts may remain about whether the burden of disease warrants vaccine introduction, whether the administration of the vaccine in public health programs will be cost-effective, whether vaccine introduction will be programmatically feasible and acceptable, and whether the introduction of the vaccine will be financially sustainable. To address these residual doubts, a third type of translational research is needed. Since its inception in 1987, the International Vaccine Institute, an international, non-profit research and development organization located in Seoul, Korea, has conducted translational research on new vaccine introduction for a variety of diseases in 22 countries in Asia, Africa and Latin America. In this paper, we describe translational research projects undertaken by the International Vaccine Institute and lessons learned about strategies to increase the impact of translational research on vaccine policy for the developing world.

Keywords:
Translational research, Vaccine introduction, Developing countries
This content is only available via PDF.
© 2008 Nestec Ltd., Vevey/S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.